Inhibikase Therapeutics (IKT) Notes Payables (2020 - 2021)
Inhibikase Therapeutics (IKT) posted quarterly Notes Payables of $248911.0 for Q4 2021, up 485.2% year-over-year from $42534.0 in Q4 2020, and little changed quarter-over-quarter from $248911.0 in Q3 2021.
Powered by 
Analysis
Inhibikase Therapeutics (IKT) Notes Payables (2020 - 2021) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Notes Payables for 2 consecutive years, with $248911.0 the latest figure, recorded in Q4 2021.
- In Q4 2021, Notes Payables rose 485.2% year-over-year to $248911.0; the TTM figure through Dec 2021 stood at $248911.0 (up 485.2% YoY), while the FY2021 annual figure was $248911.0, up 485.2% from the prior year.
- Notes Payables steadied at $248911.0 in Q4 2021 per IKT's latest filing, from $248911.0 in the prior quarter.
- Across five years, Notes Payables topped out at $994789.0 in Q1 2021 and bottomed at $42534.0 in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Inhibikase Therapeutics | 435.56 Mn | 276.54 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | 248,911.00 |
| Sep 30, 2021 | 248,911.00 |
| Mar 31, 2021 | 994,789.00 |
| Dec 31, 2020 | 42,534.00 |